Hospital
ST Luke's Hospital
ST Luke's Hospital was paid $6.98M by Medicaid between Jan 2018 and Jan 2024, across 188 billing codes. Its largest line is 99283, emergency room visit (moderate) — 31% of everything it billed.
33Billing provider infoST LUKE'S HOSPITAL
ALLENTOWN, PA 18102
ALLENTOWN, PA 18102
33aNPI1952399933assigned 10/12/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.98M
24GClaims157,165
24DCodes billed188
24AFirst – last monthJan 2018 – Jan 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#45 of 154
Median peer was paid$2.82M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 602 | $31K | |
| 2019 | 200 | $18K | |
| 2020 | 20,143 | $819K | |
| 2021 | 86,522 | $3.76M | |
| 2022 | 24,695 | $1.26M | |
| 2023 | 23,958 | $1.04M | |
| 2024incomplete | 1,045 | $48K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 18,402 | 17,735 | $2.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 10,099 | 9,728 | $1.48M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.1% | 3,298 | 3,129 | $633K |
| G0378 | Hospital observation service, per hour | 5.1% | 380 | 360 | $356K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.1% | 2,033 | 2,017 | $215K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.5% | 2,195 | 2,106 | $177K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 3,847 | 3,764 | $176K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 734 | 704 | $131K |
| 80050 | General health panel | 1.6% | 2,506 | 2,479 | $113K |
| 80053 | Comprehensive metabolic panel | 1.5% | 10,110 | 9,635 | $105K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 2,762 | 2,706 | $96K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 2,021 | 875 | $74K |
176 more codes
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 790 | $68K |
| 80061 | Lipid panel | <1% | 4,733 | $65K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,005 | $57K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,122 | $54K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,548 | $44K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,855 | $41K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 535 | $38K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,304 | $35K |
| 86803 | <1% | 1,653 | $32K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 109 | $30K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 370 | $29K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 137 | $28K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,109 | $27K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 271 | $26K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,122 | $25K |
| X0616 | <1% | 138 | $25K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,034 | $24K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,031 | $24K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 29 | $21K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 443 | $21K |
| 77066 | Tomosynthesis, mammo | <1% | 222 | $18K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 729 | $16K |
| 76642 | <1% | 417 | $16K | |
| 80081 | <1% | 168 | $15K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,001 | $14K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,269 | $14K |
| 82728 | <1% | 963 | $12K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,337 | $12K |
| 81001 | <1% | 3,900 | $11K | |
| 83880 | <1% | 353 | $11K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 928 | $11K |
| 83690 | <1% | 2,357 | $10K | |
| 83735 | <1% | 1,503 | $10K | |
| 82607 | <1% | 987 | $10K | |
| 87631 | <1% | 74 | $10K | |
| 87340 | <1% | 671 | $10K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 133 | $10K |
| 86480 | <1% | 124 | $9K | |
| 85027 | <1% | 1,284 | $9K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 280 | $9K |
| 73630 | <1% | 868 | $8K | |
| 83540 | <1% | 856 | $7K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,412 | $7K |
| 84484 | <1% | 849 | $7K | |
| 84439 | <1% | 828 | $7K | |
| 84153 | <1% | 269 | $7K | |
| 84702 | <1% | 405 | $7K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 172 | $6K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 79 | $6K |
| 82784 | <1% | 252 | $6K | |
| 71250 | <1% | 90 | $6K | |
| 82570 | <1% | 802 | $6K | |
| 76536 | <1% | 115 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 743 | $6K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 318 | $6K |
| 86003 | <1% | 38 | $5K | |
| 82043 | <1% | 634 | $5K | |
| 83970 | <1% | 121 | $5K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 27 | $5K |
| J3490 | Unclassified drugs | <1% | 496 | $5K |
| 90715 | <1% | 205 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 78 | $4K |
| 72110 | <1% | 200 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 105 | $4K |
| 83550 | <1% | 831 | $4K | |
| 73610 | <1% | 304 | $4K | |
| 76770 | <1% | 101 | $4K | |
| 84403 | <1% | 142 | $4K | |
| 86592 | <1% | 924 | $4K | |
| D1110 | Prophylaxis - adult | <1% | 117 | $4K |
| 73030 | <1% | 319 | $4K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 58 | $4K |
| 85610 | <1% | 1,018 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 75 | $4K |
| 85007 | <1% | 953 | $4K | |
| 86038 | <1% | 220 | $3K | |
| 87040 | <1% | 181 | $3K | |
| 73564 | <1% | 225 | $3K | |
| 73130 | <1% | 342 | $3K | |
| 86618 | <1% | 124 | $3K | |
| 85730 | <1% | 503 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 56 | $3K |
| 73562 | <1% | 208 | $3K | |
| 85379 | <1% | 306 | $3K | |
| 82746 | <1% | 308 | $3K | |
| 96367 | <1% | 156 | $3K | |
| 86780 | <1% | 194 | $3K | |
| 82550 | <1% | 327 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 41 | $2K |
| 86800 | <1% | 122 | $2K | |
| 86140 | <1% | 721 | $2K | |
| 83605 | <1% | 300 | $2K | |
| 80074 | <1% | 38 | $2K | |
| 93017 | <1% | 57 | $2K | |
| 83020 | <1% | 170 | $2K | |
| 85652 | <1% | 616 | $2K | |
| 93226 | <1% | 43 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 896 | $2K |
| 70486 | <1% | 24 | $2K | |
| D0120 | Dental checkup, returning patient | <1% | 91 | $2K |
| 77080 | <1% | 40 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 788 | $2K |
| 84550 | <1% | 247 | $2K | |
| 73502 | <1% | 88 | $1K | |
| 86704 | <1% | 94 | $1K | |
| 84402 | <1% | 51 | $1K | |
| 82950 | <1% | 199 | $1K | |
| 81003 | <1% | 477 | $1K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 76 | $1K |
| 83615 | <1% | 182 | $1K | |
| 87077 | <1% | 177 | $1K | |
| 72100 | <1% | 85 | $1K | |
| 87186 | <1% | 155 | $1K | |
| 73110 | <1% | 130 | $1K | |
| 86850 | <1% | 152 | $1K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $1K |
| 82948 | <1% | 666 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,792 | $1K |
| 83001 | <1% | 62 | $1K | |
| 84100 | <1% | 189 | $1K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 24 | $1K |
| 86430 | <1% | 159 | $1K | |
| 86255 | <1% | 53 | $1K | |
| 84146 | <1% | 39 | $997.44 | |
| 86376 | <1% | 124 | $993.83 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 529 | $898.44 |
| 80076 | <1% | 99 | $868.75 | |
| 93225 | <1% | 43 | $838.01 | |
| 86901 | <1% | 205 | $816.74 | |
| 86900 | <1% | 205 | $806.94 | |
| 84165 | <1% | 55 | $793.12 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 25 | $765.21 |
| 86706 | <1% | 58 | $745.66 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,333 | $606.72 |
| 83655 | <1% | 55 | $580.00 | |
| 84703 | <1% | 47 | $523.21 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,950 | $499.53 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 54 | $460.24 |
| 83002 | <1% | 24 | $455.60 | |
| 86200 | <1% | 28 | $451.40 | |
| 86705 | <1% | 27 | $443.31 | |
| 84156 | <1% | 93 | $404.51 | |
| 82785 | <1% | 26 | $399.00 | |
| 82805 | <1% | 13 | $378.88 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,102 | $371.56 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 870 | $367.74 |
| 74018 | <1% | 30 | $342.92 | |
| 72050 | <1% | 14 | $338.80 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 59 | $329.58 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 671 | $317.48 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,196 | $294.36 |
| 84145 | <1% | 19 | $293.16 | |
| 82105 | <1% | 13 | $280.00 | |
| 82553 | <1% | 27 | $272.20 | |
| 72072 | <1% | 13 | $256.60 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,406 | $245.24 |
| 73590 | <1% | 13 | $216.80 | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 16 | $198.00 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 22 | $184.55 |
| OP250 | <1% | 80 | $160.49 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 280 | $131.82 |
| D0220 | Intraoral - periapical first radiographic image | <1% | 13 | $95.55 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 234 | $92.07 |
| 82248 | <1% | 13 | $89.25 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 119 | $57.76 |
| 82077 | <1% | 86 | $42.12 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 946 | $37.63 |
| 81025 | <1% | 90 | $24.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 465 | $19.56 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 14 | $18.48 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 604 | $3.17 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 19 | $0.00 |
| A9270 | Non-covered item or service | 0% | 14 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 134 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 71 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 84 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLICHTENWALNER, THOMAS (SENIOR VP FINANCE)
| Provider | Location | Paid |
|---|---|---|
| ST Luke's Hospital | Allentown, PA | $4.97M |
| The Carbon Schuylkill Community Hospital, INC. | Tamaqua, PA | $2.00M |
| ST Luke's Hospital | Lehighton, PA | $1.16M |
| The Carbon-Schuylkill Community Hospital, INC. | Lansford, PA | $758K |
| The Carbon-Schuylkill Community Hospital, INC. | Ringtown, PA | $393K |
| GSLPG, INC | Orwigsburg, PA | $31K |
| ST. Luke's Hospital | Palmerton, PA | $607.60 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.